



(51) International Patent Classification:

A61P 35/02 (2006.01) C07K 16/46 (2006.01)
C07K 16/28 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2022/052126

(22) International Filing Date:

09 March 2022 (09.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/158,539 09 March 2021 (09.03.2021) US
63/172,973 09 April 2021 (09.04.2021) US
63/265,184 09 December 2021 (09.12.2021) US

(71) Applicant: **MOLECULAR PARTNERS AG** [CH/CH];
Wagistrasse 14, 8952 Schlieren (CH).

(72) Inventors: **BIANCHI, Matteo**; c/o Molecular Partners
AG, Wagistrasse 14, 8952 Schlieren (CH). **RESCHKE,**

Nina; c/o Molecular Partners AG, Wagistrasse 14, 8952
Schlieren (CH). **GRIMM, Sebastien**; c/o Molecular Partners
AG, Wagistrasse 14, 8952 Schlieren (CH). **REICHEN,**
Christian; c/o Molecular Partners AG, Wagistrasse 14,
8952 Schlieren (CH). **SCHLERETH, Bernd**; c/o Molec-
ular Partners AG, Wagistrasse 14, 8952 Schlieren (CH).
LEVITSKY, Victor; c/o Molecular Partners AG, Wagis-
trasse 14, 8952 Schlieren (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(54) Title: NOVEL DARPIN BASED MULTI-SPECIFIC T-CELL ENGAGERS

FIGURE 1 (A-B)

FIG.1A





FIG. 1B



A. Mean vs actual time, DARPIn® protein #51
B. Mean vs actual time, DARPIn® protein #50
C. Mean vs actual time, DARPIn® protein #54
D. Mean vs actual time, DARPIn® protein #53
E. Mean vs actual time, DARPIn® protein #55

(57) Abstract: The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets., such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g.. acute myeloid leukaemia (AML), In a mammal, including a human.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))